应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
REGN 再生元制药公司
美国独立日休市 07-02 16:00:00 EDT
654.27
+29.55
+4.73%
盘后
654.27
+0.00
0.00%
19:29 EDT
最高
654.94
最低
625.70
成交量
107.16万
今开
630.52
昨收
624.72
日振幅
4.68%
总市值
691.69亿
流通市值
675.88亿
总股本
1.06亿
成交额
6.93亿
换手率
1.04%
流通股本
1.03亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
异动解读｜再生元制药盘中上涨3.1%，入选FDA生产试点叠加创新药审评利好
行情直击 · 07-02 22:53
异动解读｜再生元制药盘中上涨3.1%，入选FDA生产试点叠加创新药审评利好
美国FDA启动预审试点项目，安尼尔、Cellares、礼来、富士胶片等多家企业参与
美股速递 · 06-30
美国FDA启动预审试点项目，安尼尔、Cellares、礼来、富士胶片等多家企业参与
礼来、再生元制药等首批入选FDA加速新生产设施审批计划
美股速递 · 06-30
礼来、再生元制药等首批入选FDA加速新生产设施审批计划
市场消息：礼来、再生元等首批企业入选美国食品药品监督管理局全新审批提速项目，该项目旨在加快新生产厂房的审核流程。
智通财经 · 06-30
市场消息：礼来、再生元等首批企业入选美国食品药品监督管理局全新审批提速项目，该项目旨在加快新生产厂房的审核流程。
再生元制药(REGN)重症肌无力创新药获美欧监管受理 有望成全球首款治疗该症的siRNA药物
金吾财讯 · 06-22
再生元制药(REGN)重症肌无力创新药获美欧监管受理 有望成全球首款治疗该症的siRNA药物
再生元制药Cemdisiran新药申请获FDA优先审评资格，目标审评日期定于2026年11月
美股速递 · 06-22
再生元制药Cemdisiran新药申请获FDA优先审评资格，目标审评日期定于2026年11月
再生元制药公司旗下药物Cemdisira的欧盟审批决定预计于2027年下半年揭晓
美股速递 · 06-22
再生元制药公司旗下药物Cemdisira的欧盟审批决定预计于2027年下半年揭晓
异动解读｜再生元制药公司盘中下跌3.07%，三期临床失败叠加Eylea生物类似药申请重压
行情直击 · 06-09
异动解读｜再生元制药公司盘中下跌3.07%，三期临床失败叠加Eylea生物类似药申请重压
Parabilis Medicines拟将约1.5亿美元IPO收益用于继续推进Zolucatetide治疗硬纤维瘤的临床开发
美股速递 · 06-04
Parabilis Medicines拟将约1.5亿美元IPO收益用于继续推进Zolucatetide治疗硬纤维瘤的临床开发
Parabilis Medicines宣布与再生元制药达成协议，后者将斥资约7500万美元在同步私募中认购其普通股
美股速递 · 06-04
Parabilis Medicines宣布与再生元制药达成协议，后者将斥资约7500万美元在同步私募中认购其普通股
异动解读｜再生元制药公司盘中上涨3.07%，埃博拉抗体获世卫组织推荐叠加合作扩展提振
行情直击 · 06-04
异动解读｜再生元制药公司盘中上涨3.07%，埃博拉抗体获世卫组织推荐叠加合作扩展提振
CytomX与再生元制药公司达成新协议：再生元获得6个额外靶点的选择权，潜在里程碑总额高达约40亿美元
美股速递 · 06-03
CytomX与再生元制药公司达成新协议：再生元获得6个额外靶点的选择权，潜在里程碑总额高达约40亿美元
再生元制药公司：Maftivimab在体外对包括邦迪布焦在内的多种埃博拉病毒株展现广泛活性
美股速递 · 05-29
再生元制药公司：Maftivimab在体外对包括邦迪布焦在内的多种埃博拉病毒株展现广泛活性
再生元制药：Maftivimab获推荐作为单药疗法在当前疫情中展开研究
美股速递 · 05-29
再生元制药：Maftivimab获推荐作为单药疗法在当前疫情中展开研究
再生元埃博拉抗体获世卫组织推荐，用于应对当前本迪布焦型埃博拉病毒疫情
美股速递 · 05-29
再生元埃博拉抗体获世卫组织推荐，用于应对当前本迪布焦型埃博拉病毒疫情
异动解读｜再生元制药盘中上涨3.25%，报648.97美元
行情直击 · 05-20
异动解读｜再生元制药盘中上涨3.25%，报648.97美元
再生元制药公司同意在并行私募中收购Parabilis Medicines约7500万美元普通股
美股速递 · 05-20
再生元制药公司同意在并行私募中收购Parabilis Medicines约7500万美元普通股
再生元制药公司：协议包含约22亿美元额外潜在里程碑付款及分级特许权使用费
美股速递 · 05-18
再生元制药公司：协议包含约22亿美元额外潜在里程碑付款及分级特许权使用费
再生元制药公司：根据协议条款，公司追加期权付款后可能推进更多靶点研究
美股速递 · 05-18
再生元制药公司：根据协议条款，公司追加期权付款后可能推进更多靶点研究
再生元制药公司：Leerink Partners下调评级至“与大盘持平”，目标价大幅削减至641美元
美股速递 · 05-18
再生元制药公司：Leerink Partners下调评级至“与大盘持平”，目标价大幅削减至641美元
加载更多
公司概况
公司名称：
再生元制药公司
所属市场：
NASDAQ
上市日期：
--
主营业务：
再生元制药公司于1988年在纽约州注册成立。该公司是一家完全整合的生物技术公司，为患有严重疾病的人发明、开发、制造和商业化药物。其核心业务战略建立在科研和专有技术的强大基础之上，推进跨多个治疗领域的多样化产品和候选产品组合。
发行价格：
--
{"stockData":{"symbol":"REGN","market":"US","secType":"STK","nameCN":"再生元制药公司","latestPrice":654.27,"timestamp":1783022400000,"preClose":624.72,"halted":0,"volume":1071604,"hourTrading":{"tag":"盘后","latestPrice":654.27,"preClose":654.27,"latestTime":"19:29 EDT","volume":44374,"amount":29032209.809,"timestamp":1783034982098,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.04730119093353815,"floatShares":103302739,"shares":105719806,"eps":41.06084,"marketStatus":"美国独立日休市","change":29.55,"latestTime":"07-02 16:00:00 EDT","open":630.52,"high":654.935,"low":625.7,"amount":693476633.7956,"amplitude":0.046797,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":41.06084,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1783324800000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":624.72,"dividendRate":0.005563,"preHourTrading":{"tag":"盘前","latestPrice":624.72,"preClose":624.72,"latestTime":"08:34 EDT","volume":190,"amount":118654.16399999999,"timestamp":1782995689194,"change":0,"changeRate":0,"amplitude":0.02241},"postHourTrading":{"tag":"盘后","latestPrice":654.27,"preClose":654.27,"latestTime":"19:29 EDT","volume":44374,"amount":29032209.809,"timestamp":1783034982098,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.1555909644358104,"impliedVol":0.334,"impliedVolPercentile":0.3506},"requestUrl":"/m/hq/s/REGN","defaultTab":"news","newsList":[{"id":"1160625822","title":"异动解读｜再生元制药盘中上涨3.1%，入选FDA生产试点叠加创新药审评利好","url":"https://stock-news.laohu8.com/highlight/detail?id=1160625822","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160625822?lang=zh_cn&edition=full","pubTime":"2026-07-02 22:53","pubTimestamp":1783003990,"startTime":"0","endTime":"0","summary":"7月2日，再生元制药盘中上涨3.1%，报644.15美元/股，成交额8873.73万美元。消息面上，公司近期迎来多重利好催化。6月29日，美国FDA宣布再生元制药入选其新推出的PreCheck生产试点项目，该项目为企业提供更早期的监管沟通，提升美国本土药品生产的可预测性。此外，6月22日公司重症肌无力创新药Cemdisiran新药申请获FDA优先审评资格，目标审评日期定于11月，欧洲药品管理局亦同步受理。Cemdisiran若获批，有望成为全球首款治疗全身型重症肌无力的siRNA药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113725546","title":"美国FDA启动预审试点项目，安尼尔、Cellares、礼来、富士胶片等多家企业参与","url":"https://stock-news.laohu8.com/highlight/detail?id=1113725546","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113725546?lang=zh_cn&edition=full","pubTime":"2026-06-30 04:30","pubTimestamp":1782765004,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局的“预审”试点项目迎来了一批重量级参与者。该计划旨在优化新药和疗法的审查流程，而此次加入的安尼尔制药、Cellares、礼来、富士胶片、Kriya、协和麒麟以及再生元制药等公司，无疑为项目注入了强大的行业动力。这一举措标志着FDA在推动监管科学创新、加速潜在疗法上市方面迈出了新的一步。通过让领先的制药与生物技术公司提前介入，FDA期望能更高效地识别和解决开发过程中的关键问题，从而最终惠及等待新疗法的患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0096364046.USD","LU2087625088.SGD","LU0456855351.SGD","LU2236285917.USD","LU0320765059.SGD","LU2461242641.AUD","LU0198837287.USD","LU2361044865.SGD","IE00B1XK9C88.USD","LU2271345857.HKD","LLY","LU1868836914.USD","LU1551013425.SGD","LU1917777945.USD","LU0466842654.USD","IE00BJLML261.HKD","LU0889565916.HKD","LU2360106947.USD","LU0432979614.USD","LU0353189680.USD","LU1629891620.HKD","BK4581","KYKOF","ELIS","LU2106854487.HKD","BK4007","LU2023250330.USD","BK4585","LU0234572021.USD","LU0471298694.HKD","LU1720051108.HKD","LU2746668974.SGD","SG9999015945.SGD","LU2552382132.HKD","IE00BJJMRZ35.SGD","LU1064131342.USD","IE00B2B36J28.USD","LU2089284900.SGD","SG9999014906.USD","SGXZ57979304.SGD","LU0823416689.USD","LU0708995401.HKD","LU2168564495.EUR","LU2896262040.SGD","LU1366192091.USD","LU1035775433.USD","LU0203201768.USD","SG9999014880.SGD","IE00BK4W5M84.HKD","LU0820561909.HKD","LU1720051017.SGD","LU1145028129.USD","LU1868836757.USD","BK4139","LU0943347566.SGD","LU2491049909.HKD","LLII","LU0133085943.USD","LU0823434583.USD","LU1093756168.USD","LU2168564149.EUR","LU2237443622.USD","LU2361045086.USD","SG9999015986.USD","IE0002141913.USD","LU2213496289.HKD","LU2265009873.SGD","LU1267930730.SGD","LU1983299246.USD","IE00B7KXQ091.USD","REGN","LU2168564222.USD","LU0787776722.HKD","LU0225283273.USD","LU2462157665.USD","SG9999018865.SGD","LU0097036916.USD","LU2357305700.SGD","LU2417539215.USD","SG9999013999.USD","LU1023059063.AUD","BK4516","LU0471298777.SGD","LLYX","LU2237438978.USD","LU0158827781.USD","BK4533","IE00BWXC8680.SGD","LU2361044949.HKD","LU2602419157.SGD","LU0256863902.USD","LU1548497426.USD","LU2750360641.GBP","LU0256863811.USD","LU0820561818.USD","BK4534","LU2750360997.AUD","SG9999014914.USD","LU1069344957.HKD","LU1323610961.USD","LU0683600562.USD","LU0079474960.USD","LU2471134523.USD","LU2471134952.CNY","LU1061106388.HKD","LU2023250504.SGD","LU0385154629.USD","IE00BJT1NW94.SGD","SGXZ99366536.SGD","LU1551013342.USD","LU0210536198.USD","LU2491050071.SGD","LU2108987350.USD","SGXZ51526630.SGD","LU2756315318.SGD","LU2471134879.HKD","LU0122379950.USD","LU2112291526.USD","LU0053666078.USD","LU0006306889.USD","SG9999014898.SGD","LU2756315664.SGD","IE0005OL40V9.USD","LU1974910355.USD","IE00BFTCPJ56.SGD","LU1623119135.USD","IE00B4JS1V06.HKD","LU2168564065.EUR","LU2746668461.USD","LU0109394709.USD","IE0004445239.USD","LU0823434740.USD","LU1868837136.USD","LU2468319806.SGD","LU2491050154.USD","LU2063271972.USD","LU0266013472.USD","LU2362540622.SGD","LU2089984988.USD","BK4170","IE00BKDWB100.SGD","SG9999015978.USD","LU0353189763.USD","LU0058720904.USD","LU1093756325.SGD","LU0203202063.USD","LU2237443978.SGD","IE00B4R5TH58.HKD","BK4588","LU0882574139.USD","ELIL","LU0114720955.EUR","IE00BFSS7M15.SGD","GB00BDT5M118.USD","LU1804176565.USD","LU2237443549.SGD","LU0417517546.SGD","LU1057294990.SGD","LU1989771016.USD","LU0316494557.USD","LU2089283258.USD","LU0289739699.SGD","IE00BK4W5L77.USD","LU2237443895.HKD","LU2111349929.HKD","LU0354030438.USD","LU1291159041.SGD","LU2456880835.USD","LU1127390331.HKD","LU0106261372.USD","LU2028103732.USD","IE0001KFT4U8.USD","LU0158827948.USD","LU0238689110.USD","LU2552382215.SGD","SGXZ81514606.USD","LU2552382058.USD","LU2324357040.USD","IE00B1BXHZ80.USD","LU0786609619.USD","AMRX","LU0354030511.USD","LU0689472784.USD","LU0882574055.USD","BK4599","LU0061475181.USD","IE0004445015.USD","LLYZ","IE00BJJMRY28.SGD","LU0323591593.USD","LU2362541273.HKD","LU1868837300.USD","LU2471134796.USD","LU1988902786.USD","LU2023251221.USD","LU2168563687.JPY","LU1868836591.USD","SG9999015952.SGD","LU0820562030.AUD","IE0009355771.USD","IE00BKPKM429.USD","LU0094547139.USD","LU2237443382.USD","FUJIF","SG9999018857.SGD","IE00B775H168.HKD","SG9999001176.SGD","LU0964807845.USD","LU2237443465.HKD","IE00BJJMRX11.SGD","LU1280957306.USD","SG9999001176.USD","LU2264538146.SGD","SGXZ31699556.SGD","LU1814569148.SGD","LU0320765992.SGD","SG9999017495.SGD","LU0640476718.USD","LU0672654240.SGD","LU2362541513.USD","LU1712237335.SGD","LU1232071149.USD","LU2211815571.USD","IE00BN29S564.USD","IE00BFSS8Q28.SGD","LU0109391861.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139730577","title":"礼来、再生元制药等首批入选FDA加速新生产设施审批计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1139730577","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139730577?lang=zh_cn&edition=full","pubTime":"2026-06-30 02:54","pubTimestamp":1782759286,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局近日启动了一项旨在加速新生产设施审批流程的倡议，而礼来与再生元制药公司等企业已获选成为该计划的首批参与者。通过简化流程、加强前期沟通与协作，FDA期望能显著缩短药物生产设施从建设到投入运营所需的时间。业界观察人士认为，这一倡议反映了FDA在面对生物医药产业快速发展和供应链韧性需求时，正积极采取更主动、协作的监管方式。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1814569148.SGD","LU1061106388.HKD","LU0471298694.HKD","LU0058720904.USD","SG9999015978.USD","LU0289739699.SGD","ELIS","LU0354030438.USD","LU0354030511.USD","LU2237443382.USD","LU2552382058.USD","SG9999018857.SGD","REGN","LU0203201768.USD","IE0002141913.USD","LU0823434583.USD","LU1868837300.USD","IE00B1BXHZ80.USD","LU1712237335.SGD","LU0225283273.USD","IE00BK4W5L77.USD","LU1868836914.USD","LU0820562030.AUD","LU2360106947.USD","LU1868837136.USD","LU0471298777.SGD","BK4581","LU2462157665.USD","IE0005OL40V9.USD","BK4533","LU0417517546.SGD","LU2746668974.SGD","LU2491050154.USD","LU2471134796.USD","LU0708995401.HKD","LU2471134952.CNY","IE0009355771.USD","LU0889565916.HKD","IE0001KFT4U8.USD","LU0823434740.USD","LU0106261372.USD","LU2237443978.SGD","LU1548497426.USD","IE00BJT1NW94.SGD","LLY","IE00B775H168.HKD","LU1093756168.USD","LU2237443465.HKD","LU2211815571.USD","LU1280957306.USD","LU1629891620.HKD","LU0096364046.USD","IE00BKDWB100.SGD","LU2112291526.USD","LU1093756325.SGD","LU2237438978.USD","LU1868836591.USD","LU0256863811.USD","LU0133085943.USD","LU2361044865.SGD","LU2028103732.USD","LU0823416689.USD","SG9999014880.SGD","LU1720051108.HKD","SG9999014914.USD","LU1551013425.SGD","LU0432979614.USD","IE00BJJMRX11.SGD","LU1917777945.USD","LU1989771016.USD","LU2236285917.USD","IE0004445015.USD","LU1267930730.SGD","LU2357305700.SGD","LU0198837287.USD","LU2168563687.JPY","LU2491050071.SGD","IE00BWXC8680.SGD","LU2468319806.SGD","LU2108987350.USD","LU2237443549.SGD","LU0882574139.USD","LU1868836757.USD","LU0061475181.USD","LU2237443895.HKD","LU2602419157.SGD","LU0109391861.USD","LU2361044949.HKD","LU0787776722.HKD","GB00BDT5M118.USD","LU0234572021.USD","LU0786609619.USD","LU1057294990.SGD","LU2417539215.USD","LU2324357040.USD","IE00BK4W5M84.HKD","LU0097036916.USD","IE00B1XK9C88.USD","LU0109394709.USD","LU1623119135.USD","LU1974910355.USD","LU2264538146.SGD","LU1232071149.USD","LU1035775433.USD","LU2361045086.USD","LU2362541513.USD","BK4139","LU0203202063.USD","LU2461242641.AUD","SGXZ51526630.SGD","LU2168564065.EUR","SG9999014906.USD","LU1069344957.HKD","SG9999013999.USD","SGXZ57979304.SGD","LU2168564495.EUR","LLYZ","LU2471134523.USD","LU0320765059.SGD","LU0158827781.USD","LU0882574055.USD","LU2456880835.USD","LU2023251221.USD","IE00BFSS8Q28.SGD","IE00BJJMRY28.SGD","LU0640476718.USD","LU2265009873.SGD","LU0266013472.USD","LU0820561818.USD","IE00B7KXQ091.USD","SG9999018865.SGD","LU2491049909.HKD","BK4516","ELIL","LU0323591593.USD","IE00BKPKM429.USD","SG9999001176.SGD","LU0385154629.USD","LU2111349929.HKD","LU1127390331.HKD","LU0689472784.USD","IE00B4JS1V06.HKD","LU2089984988.USD","LU0006306889.USD","LU0210536198.USD","LU2237443622.USD","BK4599","LU2746668461.USD","LU2168564222.USD","SG9999015986.USD","LU1145028129.USD","LU0053666078.USD","LU2271345857.HKD","LU1064131342.USD","SG9999017495.SGD","LLII","LU1804176565.USD","SG9999001176.USD","SGXZ31699556.SGD","IE00BJLML261.HKD","LU1988902786.USD","LU0964807845.USD","LU0320765992.SGD","LU2213496289.HKD","LU2552382132.HKD","SG9999015952.SGD","LU2750360997.AUD","BK4007","IE0004445239.USD","SGXZ81514606.USD","LU2362541273.HKD","LU1291159041.SGD","LU2896262040.SGD","LU2168564149.EUR","LU0672654240.SGD","LU0820561909.HKD","LU0094547139.USD","LU1366192091.USD","LU0238689110.USD","IE00BN29S564.USD","LU2471134879.HKD","LU0353189680.USD","LU2552382215.SGD","SG9999014898.SGD","LU2362540622.SGD","IE00B4R5TH58.HKD","LU2756315318.SGD","SG9999015945.SGD","LU2087625088.SGD","BK4588","LU1551013342.USD","LU2023250330.USD","LU0114720955.EUR","LU1720051017.SGD","BK4585","IE00BFSS7M15.SGD","LU1983299246.USD","SGXZ99366536.SGD","LU1323610961.USD","LU2089284900.SGD","LU0466842654.USD","LU0943347566.SGD","IE00BJJMRZ35.SGD","LU0079474960.USD","LU0158827948.USD","LU0456855351.SGD","LU0256863902.USD","LU2063271972.USD","LU2756315664.SGD","IE00BFTCPJ56.SGD","LU0122379950.USD","LU2023250504.SGD","IE00B2B36J28.USD","BK4534","LU2106854487.HKD","LU0316494557.USD","LLYX","LU0683600562.USD","LU1023059063.AUD","LU2750360641.GBP","LU2089283258.USD","LU0353189763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647587301","title":"市场消息：礼来、再生元等首批企业入选美国食品药品监督管理局全新审批提速项目，该项目旨在加快新生产厂房的审核流程。","url":"https://stock-news.laohu8.com/highlight/detail?id=2647587301","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647587301?lang=zh_cn&edition=full","pubTime":"2026-06-30 02:53","pubTimestamp":1782759209,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1023059063.AUD","LU0820562030.AUD","LU1145028129.USD","LU1069344957.HKD","LU1280957306.USD","LU2237443622.USD","IE00BJJMRY28.SGD","IE00B1BXHZ80.USD","LU0823416689.USD","IE00BWXC8680.SGD","BK4533","SG9999001176.SGD","LU1623119135.USD","LU0133085943.USD","IE00B4R5TH58.HKD","LU0158827781.USD","LU0640476718.USD","LU0672654240.SGD","SG9999013999.USD","IE0009355771.USD","LU0122379950.USD","SG9999015978.USD","SGXZ31699556.SGD","LU2468319806.SGD","LU0353189680.USD","LU2236285917.USD","LU1868836914.USD","IE00BKDWB100.SGD","LLII","BK4588","LU0354030511.USD","LU1093756168.USD","ELIL","LU2471134879.HKD","LU1917777945.USD","LU0256863811.USD","LLY","LU0094547139.USD","LU0889565916.HKD","LU0316494557.USD","LU1291159041.SGD","LU2491050071.SGD","LU2552382058.USD","LU0256863902.USD","REGN","SG9999014880.SGD","LU0289739699.SGD","IE00BK4W5L77.USD","LU0471298694.HKD","BK4534","LU2237443978.SGD","IE00BJJMRX11.SGD","LU2089284900.SGD","SG9999014914.USD","LU1868836591.USD","LU1868837136.USD","IE00BJJMRZ35.SGD","LU1983299246.USD","LU2168564149.EUR","LU2362540622.SGD","LU2471134523.USD","SGXZ99366536.SGD","LU2028103732.USD","LU2111349929.HKD","LU2264538146.SGD","LU0882574055.USD","LLYZ","IE0004445239.USD","IE00B7KXQ091.USD","LU0823434740.USD","LU0058720904.USD","LU2237443549.SGD","LU2750360641.GBP","LU1548497426.USD","LU2168564222.USD","LU2756315318.SGD","SG9999015952.SGD","ELIS","LU2456880835.USD","LU1551013425.SGD","LU0106261372.USD","LU0061475181.USD","LU1814569148.SGD","LU2361045086.USD","SG9999015945.SGD","LU2471134796.USD","LU2756315664.SGD","BK4599","LU0266013472.USD","LU2750360997.AUD","LU2063271972.USD","LU2211815571.USD","LU0320765992.SGD","LLYX","LU0323591593.USD","IE00BN29S564.USD","LU2362541513.USD","IE00B775H168.HKD","SGXZ81514606.USD","IE00BFTCPJ56.SGD","LU2237443895.HKD","LU0820561818.USD","LU0198837287.USD","SG9999001176.USD","LU0006306889.USD","LU0238689110.USD","BK4585","LU0432979614.USD","LU1057294990.SGD","IE00B2B36J28.USD","LU2023250504.SGD","LU2168563687.JPY","SG9999015986.USD","LU1093756325.SGD","LU2168564065.EUR","SG9999018865.SGD","IE00BKPKM429.USD","LU2023251221.USD","BK4516","LU0109391861.USD","LU0823434583.USD","LU2213496289.HKD","LU0689472784.USD","LU2265009873.SGD","LU2417539215.USD","BK4581","LU2271345857.HKD","LU0964807845.USD","LU2112291526.USD","LU1232071149.USD","LU1720051108.HKD","LU2491050154.USD","LU2087625088.SGD","LU1267930730.SGD","LU1551013342.USD","LU1988902786.USD","SG9999018857.SGD","LU2324357040.USD","IE00BFSS8Q28.SGD","LU0053666078.USD","LU1989771016.USD","LU2106854487.HKD","GB00BDT5M118.USD","LU0097036916.USD","LU0109394709.USD","IE00B4JS1V06.HKD","LU2237443382.USD","LU1629891620.HKD","LU2602419157.SGD","LU2471134952.CNY","LU1720051017.SGD","LU2108987350.USD","IE0004445015.USD","LU1804176565.USD","LU0234572021.USD","SG9999017495.SGD","SGXZ57979304.SGD","SG9999014898.SGD","LU0353189763.USD","LU0786609619.USD","LU2089283258.USD","LU2361044865.SGD","LU1127390331.HKD","LU2237438978.USD","IE00BK4W5M84.HKD","LU0385154629.USD","LU0943347566.SGD","LU2360106947.USD","LU2357305700.SGD","LU2461242641.AUD","LU0708995401.HKD","LU1064131342.USD","LU2168564495.EUR","LU2361044949.HKD","IE00B1XK9C88.USD","LU0466842654.USD","IE00BJLML261.HKD","LU0096364046.USD","LU0158827948.USD","LU0203201768.USD","LU2362541273.HKD","LU2746668974.SGD","LU1366192091.USD","LU1868836757.USD","LU0320765059.SGD","BK4139","LU1035775433.USD","LU0354030438.USD","LU0417517546.SGD","LU0471298777.SGD","LU0079474960.USD","SG9999014906.USD","SGXZ51526630.SGD","LU0820561909.HKD","LU0456855351.SGD","LU1868837300.USD","BK4007","IE0005OL40V9.USD","LU2023250330.USD","LU2746668461.USD","LU2237443465.HKD","IE0002141913.USD","IE0001KFT4U8.USD","LU0203202063.USD","LU1061106388.HKD","LU0787776722.HKD","LU1974910355.USD","LU1323610961.USD","LU2552382215.SGD","LU0225283273.USD","LU0882574139.USD","LU0114720955.EUR","LU2089984988.USD","LU2491049909.HKD","LU2552382132.HKD","LU2896262040.SGD","IE00BFSS7M15.SGD","LU2462157665.USD","LU0210536198.USD","LU0683600562.USD","IE00BJT1NW94.SGD","LU1712237335.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645222700","title":"再生元制药(REGN)重症肌无力创新药获美欧监管受理 有望成全球首款治疗该症的siRNA药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2645222700","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645222700?lang=zh_cn&edition=full","pubTime":"2026-06-22 20:32","pubTimestamp":1782131526,"startTime":"0","endTime":"0","summary":"该药用于治疗抗乙酰胆腺受体抗体阳性的成人全身型重症肌无力患者。作为一款针对补体系统C5靶点的小干扰RNA疗法，Cemdisiran若能获批，有望成为全球首款用于治疗gMG的siRNA药物。目前，Cemdisiran仍处于临床研究阶段，其安全性和疗效尚未获得任何国家监管机构的最终批准。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250107/OTA0YzE0M2JmNDRmODg4Nzg5OWVhODM3NzhmNzU4MTEwODUxNDg2MTkzOA==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/OTA0YzE0M2JmNDRmODg4Nzg5OWVhODM3NzhmNzU4MTEwODUxNDg2MTkzOA==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301751","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","LU2106854487.HKD","BK4585","LU0823434740.USD","LU0823434583.USD","LU0053666078.USD","LU0320765992.SGD","REGN","LU0889565916.HKD","LU0823416689.USD","LU1974910355.USD","LU2362540622.SGD","LU2023250504.SGD","LU1917777945.USD","LU0058720904.USD","LU2089984988.USD","06978","LU0109394709.USD","LU0882574055.USD","LU2468319806.SGD","01477","BK1191","BK1574","LU2362541273.HKD","LU2362541513.USD","BK4139","BK1161","LU2237438978.USD","159992","BK4588","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131217305","title":"再生元制药Cemdisiran新药申请获FDA优先审评资格，目标审评日期定于2026年11月","url":"https://stock-news.laohu8.com/highlight/detail?id=1131217305","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131217305?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:03","pubTimestamp":1782126209,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已接受对再生元制药公司（Regeneron Pharmaceuticals）旗下药物Cemdisiran的新药申请（NDA）进行审评，并授予其优先审评资格。该申请的目标审评日期定于2026年11月。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","LU2106854487.HKD","BK4585","LU0823434740.USD","LU0823434583.USD","LU0053666078.USD","LU0320765992.SGD","REGN","LU0889565916.HKD","LU0823416689.USD","LU1974910355.USD","LU2362540622.SGD","LU2023250504.SGD","LU1917777945.USD","LU0058720904.USD","LU2089984988.USD","LU0109394709.USD","LU0882574055.USD","LU2468319806.SGD","LU2362541273.HKD","LU2362541513.USD","BK4139","LU2237438978.USD","BK4588","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118743106","title":"再生元制药公司旗下药物Cemdisira的欧盟审批决定预计于2027年下半年揭晓","url":"https://stock-news.laohu8.com/highlight/detail?id=1118743106","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118743106?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:02","pubTimestamp":1782126136,"startTime":"0","endTime":"0","summary":"再生元制药公司（Regeneron Pharmaceuticals）研发的药物Cemdisira，其欧洲市场准入的关键性裁决——欧盟委员会的审批决定，预计将在2027年下半年作出。这一时间点标志着该药物在欧洲监管流程中的一个重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","LU1917777945.USD","LU2468319806.SGD","LU2362541513.USD","LU0320765992.SGD","LU2237438978.USD","LU2106854487.HKD","LU0823416689.USD","LU0058720904.USD","LU0289739699.SGD","LU0114720955.EUR","BK4139","LU2089984988.USD","LU2362540622.SGD","LU0109394709.USD","LU0882574055.USD","LU2362541273.HKD","LU0053666078.USD","LU0889565916.HKD","LU2023250504.SGD","LU0823434583.USD","REGN","LU0823434740.USD","LU1974910355.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104752887","title":"异动解读｜再生元制药公司盘中下跌3.07%，三期临床失败叠加Eylea生物类似药申请重压","url":"https://stock-news.laohu8.com/highlight/detail?id=1104752887","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104752887?lang=zh_cn&edition=full","pubTime":"2026-06-09 00:29","pubTimestamp":1780936189,"startTime":"0","endTime":"0","summary":"6月8日，再生元制药公司盘中下跌3.07%，报615.91美元/股，成交额1.57亿美元。消息面上，多重利空共振施压股价。此外，冰岛生物制药公司Alvotech联合Teva再次向FDA提交针对再生元核心产品Eylea的生物类似药上市申请，进一步加剧市场对其眼科业务收入遭受侵蚀的担忧。同日生物科技板块整体承压，艾伯维跌2.35%、吉利德跌1.41%、安进跌1.18%，行业情绪偏弱加大下行压力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128409346","title":"Parabilis Medicines拟将约1.5亿美元IPO收益用于继续推进Zolucatetide治疗硬纤维瘤的临床开发","url":"https://stock-news.laohu8.com/highlight/detail?id=1128409346","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128409346?lang=zh_cn&edition=full","pubTime":"2026-06-04 18:21","pubTimestamp":1780568476,"startTime":"0","endTime":"0","summary":"Parabilis Medicines公司计划，将首次公开募股所筹资金中的约1.5亿美元，用于持续推动其候选药物Zolucatetide在硬纤维瘤领域的临床开发进程。此举旨在加速该疗法的研发，以应对这一临床需求未满足的疾病领域。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK4139","LU2089984988.USD","LU1974910355.USD","LU2362540622.SGD","LU2362541513.USD","LU1917777945.USD","LU0882574055.USD","LU0053666078.USD","LU0823416689.USD","BK4588","BK4585","LU0889565916.HKD","LU0320765992.SGD","LU2468319806.SGD","LU0114720955.EUR","LU2362541273.HKD","LU2023250504.SGD","LU0289739699.SGD","LU2106854487.HKD","LU0058720904.USD","REGN","LU0823434740.USD","LU0823434583.USD","LU2237438978.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111077391","title":"Parabilis Medicines宣布与再生元制药达成协议，后者将斥资约7500万美元在同步私募中认购其普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1111077391","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111077391?lang=zh_cn&edition=full","pubTime":"2026-06-04 18:20","pubTimestamp":1780568423,"startTime":"0","endTime":"0","summary":"再生元制药公司已同意在一项同步进行的私募融资中，以约7500万美元的价格购入Parabilis Medicines Inc的普通股。此项交易标志着两家生物技术公司在资本层面的重要合作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362541273.HKD","LU2106854487.HKD","LU0053666078.USD","LU0114720955.EUR","REGN","LU0882574055.USD","LU0320765992.SGD","BK4139","BK4588","LU2089984988.USD","LU0889565916.HKD","LU0823416689.USD","LU0823434740.USD","LU0289739699.SGD","LU1974910355.USD","LU0823434583.USD","LU1917777945.USD","LU2362540622.SGD","LU2468319806.SGD","LU0058720904.USD","LU0109394709.USD","BK4585","LU2362541513.USD","LU2237438978.USD","LU2023250504.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157154735","title":"异动解读｜再生元制药公司盘中上涨3.07%，埃博拉抗体获世卫组织推荐叠加合作扩展提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1157154735","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157154735?lang=zh_cn&edition=full","pubTime":"2026-06-04 00:35","pubTimestamp":1780504537,"startTime":"0","endTime":"0","summary":"6月3日，再生元制药公司盘中上涨3.07%，报621.42美元/股，成交额2.1亿美元。消息面上，多重利好共振推动股价走强。一方面，世界卫生组织推荐再生元研发的单克隆抗体Maftivimab用于应对当前本迪布焦型埃博拉病毒疫情，体外实验数据显示该药物对包括邦迪布焦病毒在内的多种埃博拉病毒株具有广泛抗病毒活性，为公司管线增添公共卫生应急价值。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133955723","title":"CytomX与再生元制药公司达成新协议：再生元获得6个额外靶点的选择权，潜在里程碑总额高达约40亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1133955723","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133955723?lang=zh_cn&edition=full","pubTime":"2026-06-03 20:05","pubTimestamp":1780488342,"startTime":"0","endTime":"0","summary":"生物技术公司CytomX与再生元制药公司之间的合作迎来了重大扩展。根据最新协议，再生元已获得针对6个额外靶点的选择权，此举有望将双方的合作范围进一步拓宽。协议条款显示，再生元制药公司为获得这些新靶点的选择权，已向CytomX支付了一笔预付款。若将现有合作中的潜在付款与此次新增的里程碑款项相结合，CytomX从这项合作中可能获得的总里程碑付款最高可达约40亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1917777945.USD","CTMX","LU2362541273.HKD","LU0109394709.USD","LU0823434740.USD","LU0882574055.USD","LU2023250504.SGD","LU2089984988.USD","LU0889565916.HKD","LU2237438978.USD","BK4139","LU0823416689.USD","LU0058720904.USD","BK4585","REGN","LU0114720955.EUR","LU2362540622.SGD","LU0053666078.USD","LU1974910355.USD","LU0320765992.SGD","LU0823434583.USD","LU0289739699.SGD","BK4588","LU2106854487.HKD","LU2362541513.USD","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194253037","title":"再生元制药公司：Maftivimab在体外对包括邦迪布焦在内的多种埃博拉病毒株展现广泛活性","url":"https://stock-news.laohu8.com/highlight/detail?id=1194253037","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194253037?lang=zh_cn&edition=full","pubTime":"2026-05-29 04:01","pubTimestamp":1779998475,"startTime":"0","endTime":"0","summary":"再生元制药公司公布的研究数据显示，其单克隆抗体疗法Maftivimab在体外实验中，对包括邦迪布焦病毒在内的多种埃博拉病毒物种均表现出广泛的抗病毒活性。这一发现为该疗法的潜在应用范围提供了新的科学依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362540622.SGD","LU0823434740.USD","LU2023250504.SGD","LU1974910355.USD","LU2468319806.SGD","LU0053666078.USD","LU2106854487.HKD","LU2362541513.USD","LU0320765992.SGD","LU2237438978.USD","LU0823416689.USD","LU0882574055.USD","REGN","BK4585","LU0058720904.USD","BK4588","BK4139","LU0289739699.SGD","LU2089984988.USD","LU0889565916.HKD","LU2362541273.HKD","LU1917777945.USD","LU0823434583.USD","LU0114720955.EUR","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148240042","title":"再生元制药：Maftivimab获推荐作为单药疗法在当前疫情中展开研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1148240042","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148240042?lang=zh_cn&edition=full","pubTime":"2026-05-29 04:01","pubTimestamp":1779998471,"startTime":"0","endTime":"0","summary":"再生元制药公司宣布，其单克隆抗体药物Maftivimab已获建议，在当前爆发的疫情中作为单药疗法进行深入研究。这一推荐基于对该药物潜在疗效的初步评估，旨在探索其在独立使用时的安全性与有效性，为应对公共卫生挑战提供新的治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362541513.USD","LU0114720955.EUR","LU2362540622.SGD","BK4139","LU2023250504.SGD","LU0823434583.USD","LU2468319806.SGD","LU2106854487.HKD","LU0320765992.SGD","LU0882574055.USD","LU0823434740.USD","LU1917777945.USD","LU0289739699.SGD","LU2237438978.USD","LU0109394709.USD","LU0053666078.USD","LU2362541273.HKD","LU0823416689.USD","LU0058720904.USD","LU1974910355.USD","BK4588","REGN","LU0889565916.HKD","BK4585","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148009972","title":"再生元埃博拉抗体获世卫组织推荐，用于应对当前本迪布焦型埃博拉病毒疫情","url":"https://stock-news.laohu8.com/highlight/detail?id=1148009972","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148009972?lang=zh_cn&edition=full","pubTime":"2026-05-29 04:00","pubTimestamp":1779998412,"startTime":"0","endTime":"0","summary":"世界卫生组织已推荐将再生元制药公司研发的埃博拉抗体，用于应对当前爆发的本迪布焦型埃博拉病毒疫情，并建议在调查性框架下使用。这一建议旨在为应对此次疫情提供一种潜在的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0114720955.EUR","LU0823416689.USD","LU2237438978.USD","LU2468319806.SGD","BK4139","LU1917777945.USD","BK4585","LU2089984988.USD","LU2023250504.SGD","BK4588","LU0109394709.USD","LU2106854487.HKD","LU0058720904.USD","LU0823434583.USD","LU0889565916.HKD","LU2362541513.USD","LU2362540622.SGD","LU0053666078.USD","LU2362541273.HKD","REGN","LU0882574055.USD","LU1974910355.USD","LU0320765992.SGD","LU0823434740.USD","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134477169","title":"异动解读｜再生元制药盘中上涨3.25%，报648.97美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1134477169","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134477169?lang=zh_cn&edition=full","pubTime":"2026-05-20 21:54","pubTimestamp":1779285285,"startTime":"0","endTime":"0","summary":"5月20日，再生元制药盘中上涨3.25%，报648.97美元/股，成交额5288.26万美元。再生元制药所在的生物科技行业中，个股中，安进跌0.05%，Immunovant, Inc.涨25.03%，Silexion Therapeutics Corp涨112.27%，Roivant Sciences Ltd.涨11.8%，ImmunityBio, Inc.涨6.19%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164541553","title":"再生元制药公司同意在并行私募中收购Parabilis Medicines约7500万美元普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1164541553","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164541553?lang=zh_cn&edition=full","pubTime":"2026-05-20 05:00","pubTimestamp":1779224413,"startTime":"0","endTime":"0","summary":"Parabilis Medicines宣布，再生元制药公司已同意通过一项并行私募交易，购买其价值约7500万美元的普通股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","LU0320765992.SGD","LU2089984988.USD","BK4588","REGN","LU0889565916.HKD","LU2362541273.HKD","LU0109394709.USD","LU1974910355.USD","LU0053666078.USD","LU0058720904.USD","LU0823434583.USD","LU2468319806.SGD","LU2106854487.HKD","LU2023250504.SGD","LU0823434740.USD","LU0882574055.USD","LU2362540622.SGD","LU0289739699.SGD","LU1917777945.USD","LU2362541513.USD","LU0114720955.EUR","LU2237438978.USD","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142060213","title":"再生元制药公司：协议包含约22亿美元额外潜在里程碑付款及分级特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1142060213","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142060213?lang=zh_cn&edition=full","pubTime":"2026-05-18 19:01","pubTimestamp":1779102112,"startTime":"0","endTime":"0","summary":"再生元制药公司披露，最新达成的协议条款中，除了已公布的核心内容外，还包含了价值约22亿美元的额外潜在里程碑付款。\n此外，协议还设定了分级结构的特许权使用费安排，该安排将根据未来产品的商业化表现或特定销售目标的达成情况而动态调整。\n这些财务条款的加入，显著提升了此次交易的整体潜在价值，并体现了合作方对相关研发项目商业化前景的共同信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","LU2089984988.USD","LU2023250504.SGD","LU0289739699.SGD","LU2362541273.HKD","LU1917777945.USD","LU0109394709.USD","LU0058720904.USD","BK4588","LU2106854487.HKD","LU1974910355.USD","LU0882574055.USD","LU0889565916.HKD","LU2468319806.SGD","LU0320765992.SGD","BK4585","LU0114720955.EUR","LU2362540622.SGD","LU2362541513.USD","LU0823434583.USD","REGN","LU0823434740.USD","BK4139","LU0053666078.USD","LU2237438978.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167587402","title":"再生元制药公司：根据协议条款，公司追加期权付款后可能推进更多靶点研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1167587402","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167587402?lang=zh_cn&edition=full","pubTime":"2026-05-18 19:01","pubTimestamp":1779102110,"startTime":"0","endTime":"0","summary":"根据协议条款，若公司支付额外的期权付款，再生元制药公司可能启动针对更多靶点的研发项目。这一安排为该公司未来拓展研发管线提供了灵活性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","BK4585","LU2362541273.HKD","LU0114720955.EUR","LU0823434740.USD","LU0320765992.SGD","LU2023250504.SGD","LU2106854487.HKD","REGN","LU2237438978.USD","BK4139","LU0058720904.USD","LU0289739699.SGD","LU0882574055.USD","LU1974910355.USD","LU0823416689.USD","LU0053666078.USD","LU1917777945.USD","LU2089984988.USD","LU2362540622.SGD","LU2468319806.SGD","LU0823434583.USD","BK4588","LU2362541513.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190474575","title":"再生元制药公司：Leerink Partners下调评级至“与大盘持平”，目标价大幅削减至641美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1190474575","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190474575?lang=zh_cn&edition=full","pubTime":"2026-05-18 18:05","pubTimestamp":1779098717,"startTime":"0","endTime":"0","summary":"再生元制药公司（Regeneron Pharmaceuticals, REGN）的评级遭遇下调。投资机构Leerink Partners将其对该公司的投资评级从“跑赢大盘”（Outperform）调降至“与大盘持平”（Market Perform）。与此同时，该机构大幅下调了再生元制药的目标股价，从原先的792美元削减至641美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053666078.USD","LU2237438978.USD","LU0823434583.USD","LU1917777945.USD","LU0889565916.HKD","LU2106854487.HKD","LU0114720955.EUR","LU0823434740.USD","LU0289739699.SGD","LU2023250504.SGD","LU0109394709.USD","LU2362540622.SGD","LU2468319806.SGD","BK4139","LU0823416689.USD","LU1974910355.USD","LU0058720904.USD","LU0882574055.USD","LU2089984988.USD","REGN","LU0320765992.SGD","BK4588","LU2362541273.HKD","LU2362541513.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regeneron.com","stockEarnings":[{"period":"1week","weight":0.055},{"period":"1month","weight":0.0852},{"period":"3month","weight":-0.1412},{"period":"6month","weight":-0.1572},{"period":"1year","weight":0.1945},{"period":"ytd","weight":-0.1524}],"compareEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":-0.0195},{"period":"3month","weight":0.1356},{"period":"6month","weight":0.0902},{"period":"1year","weight":0.2004},{"period":"ytd","weight":0.0922}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"再生元制药公司于1988年在纽约州注册成立。该公司是一家完全整合的生物技术公司，为患有严重疾病的人发明、开发、制造和商业化药物。其核心业务战略建立在科研和专有技术的强大基础之上，推进跨多个治疗领域的多样化产品和候选产品组合。","yearOnYearQuotes":[{"month":1,"riseRate":0.514286,"avgChangeRate":0.03675},{"month":2,"riseRate":0.428571,"avgChangeRate":0.086855},{"month":3,"riseRate":0.457143,"avgChangeRate":-0.043382},{"month":4,"riseRate":0.457143,"avgChangeRate":0.014275},{"month":5,"riseRate":0.611111,"avgChangeRate":0.052257},{"month":6,"riseRate":0.444444,"avgChangeRate":0.006953},{"month":7,"riseRate":0.666667,"avgChangeRate":0.052552},{"month":8,"riseRate":0.542857,"avgChangeRate":0.022877},{"month":9,"riseRate":0.457143,"avgChangeRate":0.023281},{"month":10,"riseRate":0.4,"avgChangeRate":-0.00141},{"month":11,"riseRate":0.542857,"avgChangeRate":0.046018},{"month":12,"riseRate":0.485714,"avgChangeRate":0.043803}],"exchange":"NASDAQ","name":"再生元制药公司","nameEN":"Regeneron Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再生元制药公司(REGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再生元制药公司,REGN,再生元制药公司股票,再生元制药公司股票老虎,再生元制药公司股票老虎国际,再生元制药公司行情,再生元制药公司股票行情,再生元制药公司股价,再生元制药公司股市,再生元制药公司股票价格,再生元制药公司股票交易,再生元制药公司股票购买,再生元制药公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再生元制药公司(REGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}